Forssten Sofia D, Yeung Nicolas, Ouwehand Arthur C
DuPont Nutrition and Biosciences, Sokeritehtaantie 20, 02460 Kantvik, Finland.
Biomedicines. 2020 Apr 9;8(4):83. doi: 10.3390/biomedicines8040083.
The present study aimed to investigate whether probiotic recovery is affected when consumed together with antibiotics. Fecal samples were collected from an earlier antibiotic associated diarrhea, randomized, placebo-controlled study with a product consisting of a combination of NCFM, Lpc-37, and Bi-07, Bl-04 at equal numbers and at a total dose of 10 CFU. Fecal samples were collected during the screening visit (T0), i.e., at the time of antibiotic prescription, and then on the last day of the antibiotic treatment (T1) as well as seven days after the subject had stopped taking the antibiotic treatment (T2) and at two weeks after completing antibiotic treatment and one week after probiotic/placebo consumption stopped (T3). Samples were analyzed for the presence of the four administered strains. The study was registered at clinicaltrials.gov as NCT01596829. Detection levels of all four strains were significantly increased from T0 to T1 and returned to baseline level from T2 to T3. There were also significantly more subjects with detectable levels of Lpc-37, Bi-07, and Bl-04 at T1 and T2 compared to T0 and T3, and compared to placebo. Each of the four strains could be detected in the feces of patients apparently unaffected by the simultaneous consumption of antibiotics.
本研究旨在调查益生菌与抗生素同时服用时其恢复情况是否会受到影响。粪便样本取自一项早期的抗生素相关性腹泻随机、安慰剂对照研究，该研究使用了一种产品，其中包含等量的NCFM、Lpc - 37、Bi - 07和Bl - 04，总剂量为10 CFU。在筛查访视期间（T0），即抗生素处方开具时采集粪便样本，然后在抗生素治疗的最后一天（T1）、受试者停止服用抗生素治疗七天后（T2）以及完成抗生素治疗两周后且停止服用益生菌/安慰剂一周后（T3）采集样本。对样本进行分析以检测四种给药菌株的存在情况。该研究已在clinicaltrials.gov上注册，注册号为NCT01596829。从T0到T1，所有四种菌株的检测水平均显著升高，从T2到T3又恢复到基线水平。与T0和T3相比，以及与安慰剂相比，在T1和T2时可检测到Lpc - 37、Bi - 07和Bl - 04水平的受试者也显著更多。在显然未受同时服用抗生素影响的患者粪便中可以检测到这四种菌株中的每一种。
